Gritstone Oncology Inc (GRTS) has released an update.
The Company has delayed its Phase 2b Trial for their next-generation COVID-19 vaccine, GRT-R924, to fall 2024 after discussions with the FDA, which mandated the use of fully GMP-grade materials and other minor modifications. This postponement does not impact the Company’s other ongoing programs.
For further insights into GRTS stock, check out TipRanks’ Stock Analysis page.
